What’s New in Chronic Hepatitis

Abstract

Abstract

Today, children with chronic hepatitis B and C are treated with a few medications which have low sustained viral response rates and high virologic resistance rates. Chronic hepatitis B and C virus infections usually have a mild clinical coursein childhood. However, there is a high risk of developing serious complications suchas cirrhosis and liver cancer in these patients. Despite the development of new an-tiviral therapies, the treatment of chronic hepatitis still continues to be a major clinical problem. The aim of this article is to review of developments in the treatmentof chronic hepatitis in childhood.

Keywords

• Child,chronic hepatitis,treatment

Kronik Hepatit Tedavisinde Yenilikler

Öz

Öz

Günümüzde kronik B ve C hepatitli çocuklar kalıcı virolojik yanıt oranları düşük ve virolojik direnç oranları yüksek olan az sayıdaki ilaçla tedavi edilmektedir. Çocukluk döneminde kronik B ve C hepatit virus enfeksiyonları genellikle hafif klinik seyirlidir. Ancak, bu hastalarda siroz ve karaciğer kanseri gibi önemli komplikasyonların gelişmesi riski yüksektir. Yeni antiviral tedavilerin geliştirilmesine karşın,kronik hepatit tedavisi halen önemli bir klinik sorun olmaya devam etmektedir. Bumakalenin amacı çocukluk döneminde kronik hepatit tedavisindeki gelişmelerin gözden geçirilmesidir

Anahtar Kelimeler

• Çocuk,kronik hepatit,tedavi

Kaynakça

1. Kaynaklar 1.Vajro P, Veropalumbo C, Maddaluno S, Salerno M, Paren-ti G, Pignata C. Treatment of children with chronic viralhepatitis: what is available and what is in store. World JPediatr 2013; 9 (3): 212-20. 2.Hierro L, Fischler B. Treatment of pediatric chronic viralhepatitis B and C. Clin Res Hepatol Gastroenterol 2014;38 (4): 415-18. 3.Murray KF, Shah U, Mohan N, et al; Chronic Hepatitis Wor-king Group. Chronic hepatitis. J Pediatr Gastroenterol Nutr2008; 47 (2): 225-33. 4.Jonas MM, Block JM, Haber BA, et al; Hepatitis B Foun-dation. Treatment of children with chronic hepatitis B vi-rus infection in the United States: patient selection and the-rapeutic options. Hepatology 2010; 52 (6): 2192-205. 5.Sokal EM, Paganelli M, Wirth S, et al; European Societyof Pediatric Gastroenterology, Hepatology and Nutrition.Management of chronic hepatitis B in childhood: ESPG-HAN clinical practice guidelines: consensus of an expertpanel on behalf of the European Society of Pediatric Gas-troenterology, Hepatology and Nutrition. J Hepatol 2013;59 (4): 814-29. 6.Kasırga E. Lamivudine resistance in children with chronichepatitis B. World J Hepatol 2015; 7 (6): 896-902. 7.Jonas MM, Chang MH, Sokal E, et al. Randomized con-trolled trial of entecavir versus placebo in children with HBe-Ag-positive chronic hepatitis B. Hepatology 2015 Jul 29.doi: 10.1002/hep.28015. 8.Murray KF, Szenborn L, Wysocki J, et al. Randomized, pla-cebo-controlled trial of tenofovir disoproxil fumarate in ado-lescents with chronic hepatitis B. Hepatology 2012; 56 (6):2018-26. 9.Jonas MM, Kelly D, Pollack H, et al. Safety, efficacy, andpharmacokinetics of adefovir dipivoxil in children and ado-lescents (age 2 to <18 years) with chronic hepatitis B. He-patology 2008; 47 (6): 1863-71. 10.Chu M, Cho SM, Choe BH, Cho MH, Kwon S, Lee WK. Vi-rologic responses to add-on adefovir dipivoxil treatment ver-sus entecavir monotherapy in children with lamivudine-re-sistant chronic hepatitis B. J Pediatr Gastroenterol Nutr2012; 55 (6): 648-52. 11.Chung RT, Davis GL, Jensen DM, et al. Hepatitis C gui-dance: AASLD-IDSA recommendations for testing, mana-ging, and treating adults infected with hepatitis C virus. He-patology 2015; 62 (3): 932-54. 12.Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An up-date on the management of chronic hepatitis C: 2015 Con-sensus guidelines from the Canadian Association for theStudy of the Liver. Can J Gastroenterol Hepatol 2015; 29(1): 19-34. 13.http://www.uptodate.com/contents/hepatitis-c-virus-infec-tion-in-children 14.Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al; Peds-C Clinical Research Network. The combination of ribavi-rin and peginterferon is superior to peginterferon and pla-cebo for children and adolescents with chronic hepatitis C.Gastroenterology 2011; 140 (2): 450-58. 15.Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sus-tained virologic response rates in children with chronic he-patitis C receiving peginterferon alfa-2b plus ribavirin. JHepatol 2010; 52 (4): 501-507. 16.Jonas MM, Balistreri W, Gonzalez-Peralta RP, et al.Pegylated interferon for chronic hepatitis C in children af-fects growth and body composition: results from the pedi-atric study of hepatitis C (PEDS-C) trial. Hepatology 2012;56 (2): 523-31. 17.Jonas MM, Schwarz KB, Gonzalez-Peralta R, et al. Long-term growth outcomes in children treated for chronic he-patitis C. J Pediatr 2014; 165 (6): 1252-54. 18.Rodrigue JR, Balistreri W, Haber B, et al. Peginterferon withor without ribavirin has minimal effect on quality of life,behavioral/emotional, and cognitive outcomes in children.Hepatology 2011; 53 (5): 1468-75. 19.Narkewicz MR, Rosenthal P, Schwarz KB, Drack A, Mar-golis T, Repka MX; PEDS-C Study Group. Ophthalmolo-gic complications in children with chronic hepatitis C trea-ted with pegylated interferon. J Pediatr Gastroenterol Nutr2010; 51 (2): 183-86. 20.Ghany MG, Strader DB, Thomas DL, Seeff LB; AmericanAssociation for the Study of Liver Diseases. Diagnosis, ma-nagement, and treatment of hepatitis C: an update. Hepa-tology 2009; 49 (4): 1335-74. 21.Indolfi G, Azzari C, Resti M. Polymorphisms in theIFNL3/IL28B gene and hepatitis C: from adults to child-ren. World J Gastroenterol 2014; 20 (28): 9245-52.